What is the latest market price of Brivaracetam in 2025?

Brivaracetam (Brivaracetam), trade name: Briviact, is a new anti-epileptic drug that belongs to the category of anticonvulsants. It is widely used to treat partial seizures and is suitable for adults and epileptic children aged 1 month and above. Brivaracetam's mechanism of action is different from other anti-epileptic drugs. It mainly modulates the release of neurotransmitters by selectively binding to synaptic vesicle protein 2A (SV2A) in the brain, thereby reducing the frequency and severity of epileptic seizures.

Clinical trials of Brivaracetam have shown that the drug has a good effect in controlling partial epileptic seizures. Compared with traditional anti-epileptic drugs, Brivaracetam has relatively mild side effects and is well tolerated by patients. This makes brivaracetam a new option for many doctors when formulating epilepsy treatment plans, especially when patients have poor response to other drugs or have adverse reactions. Brivaracetam provides new hope.

However, brivaracetam is not currently available in China, which makes Chinese patients face certain challenges in obtaining the drug. Due to the lack of channels for Brivaracetam in the domestic market, patients are temporarily unable to purchase this drug directly through formal channels. In this case, some patients may choose to obtain brivaracetam from overseas markets. For example, the European original version of Brivaracetam is already on the market. The common specification is 50mg*60 tablets. Each box sells for about more than 4,000 yuan. The specific price may change due to exchange rate fluctuations.

While brivaracetam is available on the international market, there are currently no generic versions of this drug on the market. This means that patients can only choose original drugs when purchasing, and the prices are relatively high. Therefore, the financial burden of brivaracetam may become significant for patients with epilepsy who require long-term treatment. Moreover, the lack of medical insurance reimbursement will further increase the financial pressure on patients.

Reference materials:https://www.briviact.com/